These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 17032148

  • 1. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, Devogelaer JP, Hooper M, Su G, Zelenakas K, Pak J, Fashola T, Saidi Y, Eriksen EF, Reid IR.
    J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
    [Abstract] [Full Text] [Related]

  • 2. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D.
    N Engl J Med; 2005 Sep 01; 353(9):898-908. PubMed ID: 16135834
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological therapy of Paget's and other metabolic bone diseases.
    Hosking D.
    Bone; 2006 Feb 01; 38(2 Suppl 2):S3-7. PubMed ID: 16406763
    [Abstract] [Full Text] [Related]

  • 4. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A.
    Curr Med Res Opin; 2008 Mar 01; 24(3):695-705. PubMed ID: 18226324
    [Abstract] [Full Text] [Related]

  • 5. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
    Devogelaer JP, Sambrook P, Reid DM, Goemaere S, Ish-Shalom S, Collette J, Su G, Bucci-Rechtweg C, Papanastasiou P, Reginster JY.
    Rheumatology (Oxford); 2013 Jun 01; 52(6):1058-69. PubMed ID: 23365149
    [Abstract] [Full Text] [Related]

  • 6. Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
    Krane SM.
    Nat Clin Pract Rheumatol; 2006 Apr 01; 2(4):186-7. PubMed ID: 16932682
    [No Abstract] [Full Text] [Related]

  • 7. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul 01; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 8. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment.
    Alvarez L, Peris P, Guañabens N, Vidal S, Quintó L, Monegal A, Pons F, Ballesta AM, Muñoz-Gómez J.
    Rheumatology (Oxford); 2004 Jul 01; 43(7):869-74. PubMed ID: 15054158
    [Abstract] [Full Text] [Related]

  • 9. A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone.
    Walsh JP, Ward LC, Stewart GO, Will RK, Criddle RA, Prince RL, Stuckey BG, Dhaliwal SS, Bhagat CI, Retallack RW, Kent GN, Drury PJ, Vasikaran S, Gutteridge DH.
    Bone; 2004 Apr 01; 34(4):747-54. PubMed ID: 15050907
    [Abstract] [Full Text] [Related]

  • 10. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
    Sambrook PN, Roux C, Devogelaer JP, Saag K, Lau CS, Reginster JY, Bucci-Rechtweg C, Su G, Reid DM.
    Bone; 2012 Jan 01; 50(1):289-95. PubMed ID: 22061864
    [Abstract] [Full Text] [Related]

  • 11. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.
    Siris ES, Chines AA, Altman RD, Brown JP, Johnston CC, Lang R, McClung MR, Mallette LE, Miller PD, Ryan WG, Singer FR, Tucci JR, Eusebio RA, Bekker PJ.
    J Bone Miner Res; 1998 Jun 01; 13(6):1032-8. PubMed ID: 9626635
    [Abstract] [Full Text] [Related]

  • 12. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
    Merlotti D, Gennari L, Martini G, Valleggi F, De Paola V, Avanzati A, Nuti R.
    J Bone Miner Res; 2007 Oct 01; 22(10):1510-7. PubMed ID: 17605632
    [Abstract] [Full Text] [Related]

  • 13. Medical management of Paget's disease of bone: indications for treatment and review of current therapies.
    Siris ES, Lyles KW, Singer FR, Meunier PJ.
    J Bone Miner Res; 2006 Dec 01; 21 Suppl 2():P94-8. PubMed ID: 17229018
    [Abstract] [Full Text] [Related]

  • 14. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K, Lindsay R, Kriegman A, Beamer E, Zhou W.
    Bone; 2007 May 01; 40(5):1238-43. PubMed ID: 17347063
    [Abstract] [Full Text] [Related]

  • 15. Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
    Rendina D, Mossetti G, Viceconti R, Sorrentino M, Nunziata V.
    Calcif Tissue Int; 2004 Sep 01; 75(3):189-96. PubMed ID: 15148558
    [Abstract] [Full Text] [Related]

  • 16. Treatment with tiludronate has a similar effect to risedronate on Paget's disease activity assessed by bone markers and bone scintigraphy.
    Peris P, Alvarez L, Vidal S, Martínez MA, Monegal A, Guañabens N.
    Clin Exp Rheumatol; 2007 Sep 01; 25(2):206-10. PubMed ID: 17543143
    [Abstract] [Full Text] [Related]

  • 17. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.
    Reid IR, Lyles K, Su G, Brown JP, Walsh JP, del Pino-Montes J, Miller PD, Fraser WD, Cafoncelli S, Bucci-Rechtweg C, Hosking DJ.
    J Bone Miner Res; 2011 Sep 01; 26(9):2261-70. PubMed ID: 21638319
    [Abstract] [Full Text] [Related]

  • 18. Determinants of remission of Paget's disease of bone.
    Patel S, Stone MD, Coupland C, Hosking DJ.
    J Bone Miner Res; 1993 Dec 01; 8(12):1467-73. PubMed ID: 8304048
    [Abstract] [Full Text] [Related]

  • 19. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease.
    Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD.
    Arthritis Rheum; 1998 Feb 01; 41(2):354-60. PubMed ID: 9485094
    [Abstract] [Full Text] [Related]

  • 20. Biochemical assessment of Paget's disease of bone.
    Shankar S, Hosking DJ.
    J Bone Miner Res; 2006 Dec 01; 21 Suppl 2():P22-7. PubMed ID: 17229003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.